お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
966701

マイボーム腺機能不全:市場分析、疫学、市場予測 (2030年)

Meibomian Gland Dysfunction - Market Insight, Epidemiology and Market Forecast - 2030

出版日: 受注生産 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 200 Pages | 納期: 約10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
マイボーム腺機能不全:市場分析、疫学、市場予測 (2030年)
出版日: 受注生産
発行: DelveInsight Business Research LLP
ページ情報: 英文 200 Pages
納期: 約10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の主要7カ国 - 米国、欧州主要5ヶ国 (EU5:フランス・ドイツ・イタリア・スペイン・英国)、日本 - におけるマイボーム腺機能不全の疫学的動向と今後の市場見通しについて分析し、疾患の概要や市場の基本構造、現在の治療法とアンメットニーズ、有病者数の動向見通し、上市済み/治験中の治療薬のプロファイル、世界全体/各国の市場規模 (過去3年間・今後11年間分)、主な市場促進・抑制要因、といった情報を取りまとめてお届けいたします。

目次

第1章 主な考察

第2章 マイボーム腺機能不全:エグゼクティブサマリー

第3章 マイボーム腺機能不全の競合情報分析

第4章 マイボーム腺機能不全:市場概要

  • 全体的な市場シェア構造 (2017年)
  • 全体的な市場シェア構造 (2030年)

第5章 マイボーム腺機能不全:疾患概要

  • イントロダクション
  • 兆候と症状
  • 病態生理
  • 危険因子
  • 診断基準

第6章 ペイシェント・ジャーニー

第7章 マイボーム腺機能不全の疫学と患者人口

  • 疫学分析のポイント
  • 仮定と理論的根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • マイボーム腺機能不全:主要7ヶ国における疫学シナリオ (2017年~2030年)
  • 米国の疫学的動向
    • 米国国内のマイボーム腺機能不全の疫学シナリオ (2017年~2030年)
  • 欧州5ヶ国:国別の疫学的動向
    • ドイツの疫学的動向
    • フランスの疫学的動向
    • イタリアの疫学的動向
    • スペインの疫学的動向
    • 英国の疫学的動向
  • 日本の疫学的動向

第8章 治療アルゴリズム、現在の治療・診療方法

  • マイボーム腺機能不全の治療・管理方法
  • マイボーム腺機能不全の治療アルゴリズム

第9章 アンメットニーズ

第10章 マイボーム腺機能不全治療の主要エンドポイント

第11章 上市済み製品

  • 主要7ヶ国で販売されている製品の一覧
  • 薬名:企業名
    • 製品説明
    • 規制のマイルストーン
    • その他の開発活動
    • 重要な治験:概要

第12章 新たな治療薬

  • 主要製品の一覧
  • 薬名:企業名
    • 製品説明
    • その他の開発活動
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル

第13章 マイボーム腺機能不全:主要7ヶ国の市場分析

  • 分析の主なポイント
  • マイボーム腺機能不全の市場規模:主要7ヶ国
  • マイボーム腺機能不全の市場規模:主要7ヶ国、治療薬別

第14章 属性分析

第15章 主要7ヶ国:市場の将来展望

  • 米国の市場規模
    • マイボーム腺機能不全の全体的な市場規模
    • 市場規模:治療薬別
  • 欧州主要5ヶ国 (EU5) 市場:市場規模と将来展望
    • ドイツの市場規模
    • フランスの市場規模
    • イタリアの市場規模
    • スペインの市場規模
    • 英国の市場規模
  • 日本市場:市場規模と将来展望

第16章 マイボーム腺機能不全のアクセスと医療費償還:概要

第17章 業界の有識者 (KOL) の見解

第18章 市場促進要因

第19章 市場阻害要因

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

図表

List of Tables

  • Table 1: 7MM Meibomian Gland Dysfunction Epidemiology (2017-2030)
  • Table 2: 7MM Meibomian Gland Dysfunction Diagnosed and Treatable Cases (2017-2030)
  • Table 3: Meibomian Gland Dysfunction Epidemiology in the United States (2017-2030)
  • Table 4: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Meibomian Gland Dysfunction Epidemiology in Germany (2017-2030)
  • Table 6: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Meibomian Gland Dysfunction Epidemiology in France (2017-2030)
  • Table 8: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Meibomian Gland Dysfunction Epidemiology in Italy (2017-2030)
  • Table 10: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Meibomian Gland Dysfunction Epidemiology in Spain (2017-2030)
  • Table 12: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Meibomian Gland Dysfunction Epidemiology in the UK (2017-2030)
  • Table 14: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15: Meibomian Gland Dysfunction Epidemiology in Japan (2017-2030)
  • Table 16: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20: Region-wise Market Size in USD, Million (2017-2030)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22: United States Market Size in USD, Million (2017-2030)
  • Table 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24: Germany Market Size in USD, Million (2017-2030)
  • Table 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26: France Market Size in USD, Million (2017-2030)
  • Table 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28: Italy Market Size in USD, Million (2017-2030)
  • Table 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30: Spain Market Size in USD, Million (2017-2030)
  • Table 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34: Japan Market Size in USD, Million (2017-2030)
  • Table 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Meibomian Gland Dysfunction Epidemiology (2017-2030)
  • Figure 2: 7MM Meibomian Gland Dysfunction Diagnosed and Treatable Cases (2017-2030)
  • Figure 3: Meibomian Gland Dysfunction Epidemiology in the United States (2017-2030)
  • Figure 4: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Meibomian Gland Dysfunction Epidemiology in Germany (2017-2030)
  • Figure 6: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Meibomian Gland Dysfunction Epidemiology in France (2017-2030)
  • Figure 8: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Meibomian Gland Dysfunction Epidemiology in Italy (2017-2030)
  • Figure 10: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Meibomian Gland Dysfunction Epidemiology in Spain (2017-2030)
  • Figure 12: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Meibomian Gland Dysfunction Epidemiology in the UK (2017-2030)
  • Figure 14: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15: Meibomian Gland Dysfunction Epidemiology in Japan (2017-2030)
  • Figure 16: Meibomian Gland Dysfunction Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20: Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22: United States Market Size in USD, Million (2017-2030)
  • Figure 23: United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24: Germany Market Size in USD, Million (2017-2030)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26: France Market Size in USD, Million (2017-2030)
  • Figure 27: France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28: Italy Market Size in USD, Million (2017-2030)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30: Spain Market Size in USD, Million (2017-2030)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32: United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34: Japan Market Size in USD, Million (2017-2030)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2017-2030)

The list of figures is not exhaustive; the final content may vary.

目次
Product Code: DIMI1104

DelveInsight's "Meibomian Gland Dysfunction - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Meibomian Gland Dysfunction, historical and forecasted epidemiology as well as the Meibomian Gland Dysfunction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Meibomian Gland Dysfunction market report provides current treatment practices, emerging drugs, Meibomian Gland Dysfunction market share of the individual therapies, current and forecasted Meibomian Gland Dysfunction market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Meibomian Gland Dysfunction treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Meibomian Gland Dysfunction Disease Understanding and Treatment Algorithm

The DelveInsight Meibomian Gland Dysfunction market report gives a thorough understanding of the Meibomian Gland Dysfunction by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Meibomian Gland Dysfunction.

Treatment

It covers the details of conventional and current medical therapies available in the Meibomian Gland Dysfunction market for the treatment of the condition. It also provides Meibomian Gland Dysfunction treatment algorithms and guidelines in the United States, Europe, and Japan.

Meibomian Gland Dysfunction Epidemiology

The Meibomian Gland Dysfunction epidemiology division provide insights about historical and current Meibomian Gland Dysfunction patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Meibomian Gland Dysfunction epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Meibomian Gland Dysfunction Epidemiology

The epidemiology segment also provides the Meibomian Gland Dysfunction epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Meibomian Gland Dysfunction Drug Chapters

Drug chapter segment of the Meibomian Gland Dysfunction report encloses the detailed analysis of Meibomian Gland Dysfunction marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Meibomian Gland Dysfunction clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Meibomian Gland Dysfunction treatment.

Meibomian Gland Dysfunction Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Meibomian Gland Dysfunction treatment.

Meibomian Gland Dysfunction Market Outlook

The Meibomian Gland Dysfunction market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Meibomian Gland Dysfunction market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Meibomian Gland Dysfunction market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Meibomian Gland Dysfunction market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Meibomian Gland Dysfunction market in 7MM.

The United States Market Outlook

This section provides the total Meibomian Gland Dysfunction market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Meibomian Gland Dysfunction market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Meibomian Gland Dysfunction market size and market size by therapies in Japan is also mentioned.

Meibomian Gland Dysfunction Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Meibomian Gland Dysfunction market or expected to get launched in the market during the study period 2017-2030. The analysis covers Meibomian Gland Dysfunction market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Meibomian Gland Dysfunction Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Meibomian Gland Dysfunction key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Meibomian Gland Dysfunction emerging therapies.

Reimbursement Scenario in Meibomian Gland Dysfunction

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Meibomian Gland Dysfunction domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Meibomian Gland Dysfunction market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Meibomian Gland Dysfunction Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Meibomian Gland Dysfunction, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Meibomian Gland Dysfunction epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Meibomian Gland Dysfunction are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Meibomian Gland Dysfunction market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Meibomian Gland Dysfunction market

Report Highlights:

  • In the coming years, Meibomian Gland Dysfunction market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Meibomian Gland Dysfunction R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Meibomian Gland Dysfunction. Launch of emerging therapies will significantly impact the Meibomian Gland Dysfunction market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Meibomian Gland Dysfunction
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Meibomian Gland Dysfunction Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Meibomian Gland Dysfunction Pipeline Analysis
  • Meibomian Gland Dysfunction Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Meibomian Gland Dysfunction Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Meibomian Gland Dysfunction Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Meibomian Gland Dysfunction Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Meibomian Gland Dysfunction market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Meibomian Gland Dysfunction total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Meibomian Gland Dysfunction market size during the forecast period (2017-2030)?
  • At what CAGR, the Meibomian Gland Dysfunction market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Meibomian Gland Dysfunction market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Meibomian Gland Dysfunction market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Meibomian Gland Dysfunction?
  • What is the historical Meibomian Gland Dysfunction patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Meibomian Gland Dysfunction in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Meibomian Gland Dysfunction?
  • Out of all 7MM countries, which country would have the highest prevalent population of Meibomian Gland Dysfunction during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Meibomian Gland Dysfunction treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Meibomian Gland Dysfunction in the USA, Europe, and Japan?
  • What are the Meibomian Gland Dysfunction marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Meibomian Gland Dysfunction ?
  • How many therapies are developed by each company for Meibomian Gland Dysfunction treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Meibomian Gland Dysfunction treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Meibomian Gland Dysfunction therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Meibomian Gland Dysfunction and their status?
  • What are the key designations that have been granted for the emerging therapies for Meibomian Gland Dysfunction ?
  • What are the global historical and forecasted market of Meibomian Gland Dysfunction?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Meibomian Gland Dysfunction market
  • To understand the future market competition in the Meibomian Gland Dysfunction market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Meibomian Gland Dysfunction in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Meibomian Gland Dysfunction market
  • To understand the future market competition in the Meibomian Gland Dysfunction market

Table of Contents

1. Key Insights

2. Executive Summary of Meibomian Gland Dysfunction

3. Competitive Intelligence Analysis for Meibomian Gland Dysfunction

4. Meibomian Gland Dysfunction: Market Overview at a Glance

  • 4.1. Meibomian Gland Dysfunction Total Market Share (%) Distribution in 2017
  • 4.2. Meibomian Gland Dysfunction Total Market Share (%) Distribution in 2030

5. Meibomian Gland Dysfunction: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Meibomian Gland Dysfunction Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Meibomian Gland Dysfunction Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Meibomian Gland Dysfunction Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Meibomian Gland Dysfunction Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Meibomian Gland DysfunctionEpidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Meibomian Gland Dysfunction Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Meibomian Gland Dysfunction Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Meibomian Gland Dysfunction Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Meibomian Gland Dysfunction Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Meibomian Gland Dysfunction Treatment and Management
  • 8.2. Meibomian Gland Dysfunction Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Meibomian Gland Dysfunction Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Meibomian Gland Dysfunction: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Meibomian Gland Dysfunction Market Size in 7MM
  • 13.3. Meibomian Gland Dysfunction Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Meibomian Gland Dysfunction Total Market Size in the United States
    • 15.1.2. Meibomian Gland Dysfunction Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Meibomian Gland Dysfunction Total Market Size in Germany
    • 15.3.2. Meibomian Gland Dysfunction Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Meibomian Gland Dysfunction Total Market Size in France
    • 15.4.2. Meibomian Gland Dysfunction Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Meibomian Gland Dysfunction Total Market Size in Italy
    • 15.5.2. Meibomian Gland Dysfunction Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Meibomian Gland Dysfunction Total Market Size in Spain
    • 15.6.2. Meibomian Gland Dysfunction Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Meibomian Gland Dysfunction Total Market Size in the United Kingdom
    • 15.7.2. Meibomian Gland Dysfunction Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Meibomian Gland Dysfunction Total Market Size in Japan
    • 15.8.3. Meibomian Gland Dysfunction Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Meibomian Gland Dysfunction

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.